Prime Medicine, Inc. (PRME)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.70-0.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Prime Medicine leads in precise gene editing technology. It aims to fund operations into 2027 with current cash. The company has a strong pipeline targeting serious diseases. Recent momentum improved by 22.8 points, showing progress.
The company is loss-making with negative EPS expected through 2027. Cash burn concerns threaten funding beyond 2027. Recent earnings misses and management changes raise execution risks.
The market prices in high growth optionality with implied 3-year growth near 73%. Our fair value at $0.76 reflects cautious optimism but recognizes ongoing losses and cash risks.
Breaks if: cash reserves fall below operating expense needs before end of 2027
Prime Medicine aims to fund its operating expenses and capital expenditure requirements into 2027 using its current cash, cash equivalents, and investments.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. PRME is currently navigating a loss-making phase while focusing on advancing its clinical developments and regulatory engagements.
The market appears to have priced in a level of fragility due to its expensive valuation relative to peers. There is an expectation that the company will continue to face challenges, given its current losses and mixed recent performance.
Management is working on important clinical trials and regulatory submissions, but the recent financial performance has been neutral. The company is at risk of missing estimates, although the near-term miss probability is relatively low.
The long-term thesis hinges on the outcomes of clinical trials and regulatory approvals, as well as broader sector performance. If key healthcare companies continue to perform well, it could positively impact PRME.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$0.99 in FY26 or fails to improve in FY27
Breaks if: significant delays or failures in key clinical programs
Over the next 1 to 3 years, PRME's trajectory will depend on its ability to advance its clinical programs and navigate market challenges. Not investment advice.